GSK press releases
Follow
Arexvy recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices
Over 13 million adults aged 50-59 at increased risk in the US can potentially benefit from RSV immunisation.
